{
  "docId": "019de075-5029-738c-8512-9456f77efe7c",
  "docSlug": "25c628cfc0779f52594519f9e322dc70",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 38,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide outlines a randomized, open-label trial comparing Olvi-Vec + Platinum-doublet + Bevacizumab against a standard comparator arm.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-5029-738c-8512-9456f77efe7c/18",
  "deckHref": "/decks/019de075-5029-738c-8512-9456f77efe7c",
  "deckJsonHref": "/decks/019de075-5029-738c-8512-9456f77efe7c.json",
  "deckAnchorHref": "/decks/019de075-5029-738c-8512-9456f77efe7c#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.2,
        "y": 0.78
      },
      "kind": "callout",
      "text": "A platinum resensitizing agent is a long-standing desirable and highly demanded mechanism of action of Gyn-Oncs, their so-call “Holy Grail”.*",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "746f2aa2-6126-4b47-a617-01b51a230827",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.3,
        "y": 0.28
      },
      "kind": "diagram",
      "text": "Multi-center, randomized open-label n=186. Experimental Arm: Olvi-Vec + Platinum-doublet + Bevacizumab. Active Comparator Arm: Platinum-doublet + Bevacizumab.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97f06eea-bb45-4815-a444-2a8fdc8c4676",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.02,
        "y": 0.3
      },
      "kind": "list",
      "text": "Key Inclusion Criteria: High-grade serous, endometrioid, or clear-cell ovarian cancer; Platinum-resistant or -refractory disease; Received prior bevacizumab; Received min 3 prior lines of therapy; ECOG 0 or 1.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d409118-c8f7-43da-a12b-db1e0b347741",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.15,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Trial design intends to replicate previous data showing anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the tumor microenvironment",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47a73890-06c1-4250-8377-4ce545954ae3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.7,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "*Journal of Investigative Medicine High Impact Case Reports, Volume 6: 1–3, 2018 DOI: 10.1177/2324709618760080 Journals.sagepub.com/home/hic",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be78b14c-3918-4e89-a05c-4b4b5d661dfd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.26,
        "x": 0.72,
        "y": 0.28
      },
      "kind": "table",
      "text": "Primary Endpoint: Progression-Free Survival. Key Secondary Endpoints: AEs, DOR, ORR, OS.",
      "attrs": null,
      "subkind": "kpi",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0c114c7-0af0-4b23-a9d2-fb0f3bda748d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e80dd1aa-b998-4174-9719-2462100ab3a3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "1368a398-ce51-4172-8d87-f520b85c3a1e",
      "evidence": "list/bullet: Key Inclusion Criteria: High-grade serous, endometrioid, or clear-cell ovarian cancer; Platinum-resistant or -refractory disease; Received prior bevacizumab; Received min 3 prior lines of therapy; ECOG 0 or 1.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "e2fc6fbf-8c65-4bae-90e7-28f28d08d326",
      "evidence": "Standard structure for reporting clinical trial protocols (Inclusion criteria, arms, endpoints)",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 20,
      "from": 18,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "4ce0d94f-89df-47d1-ae65-000e13065e65",
      "evidence": "The presentation highlights the phase 3 pivotal trial design and the encouraging data from the phase 1b trial, showcasing the potential for Olvi-Vec to generate returns for investors.",
      "position": 1,
      "objective": "To present Olvi-Vec as a quick win and a big bet for investors, highlighting its potential for growth and returns",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}